Screener
Intellia Therapeutics NTLA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 4,284 | 4,972 |
| Loss on disposal of property and equipment | 153 | - |
| Stock-based compensation | 31,554 | 43,876 |
| Accretion of investment discounts | (1,149) | (3,947) |
| Change in fair value of investments, net | 575 | 786 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 2,147 | (2,836) |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's stock-based comp?
- Intellia Therapeutics (NTLA) reported stock-based comp of $18.08M in Q2 2026.
- How has Intellia Therapeutics's stock-based comp changed year-over-year?
- Intellia Therapeutics's stock-based comp decreased by 18.0% year-over-year, from $22.04M to $18.08M.
- What is the long-term trend for Intellia Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Intellia Therapeutics's stock-based comp has grown at a 14.3% compound annual growth rate (CAGR), from $47.01M to $80.22M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Intellia Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude